As per the letter enclosed.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Eye Hospital reported audited FY25 results with revenue from operations at Rs. 397.15 Cr, up ~24.4% from Rs. 319.30 Cr in FY24. EBITDA grew ~28.7% to Rs. 123.59 Cr, with margins improving slightly to ~31.1%. Net profit rose ~17.9% to Rs. 54.65 Cr, translating to EPS of Rs. 116.28. The Board recommended a final dividend of Rs. 3.50/share, taking total FY25 dividend to Rs. 6.00/share (60%). Deloitte Haskins & Sells issued an unmodified opinion, with S.R. Batliboi & Associates LLP appointed as new statutory auditor for 5 years as Deloitte's term ends. Dr. Amar Agarwal and Dr. Athiya Agarwal were reappointed as Chairman-cum-MD and Whole-time Director respectively for 3 years.
Strong top-line growth of 24%+ with steady margin expansion signals healthy operational momentum, though PAT growth of ~18% lagged revenue growth due to higher depreciation and finance costs from expansion-related capex of Rs. 102.86 Cr. Shareholders benefit from a 60% total dividend payout and continuity in leadership, while the auditor transition appears routine (end-of-term, not mid-year).